Keros Therapeutics (KROS) Competitors $14.07 +0.54 (+3.99%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$14.07 0.00 (0.00%) As of 04/17/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. MIRM, BLTE, DNLI, RXRX, BHVN, BHC, TARS, NAMS, HRMY, and AAPGShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Mirum Pharmaceuticals (MIRM), Belite Bio (BLTE), Denali Therapeutics (DNLI), Recursion Pharmaceuticals (RXRX), Biohaven (BHVN), Bausch Health Companies (BHC), Tarsus Pharmaceuticals (TARS), NewAmsterdam Pharma (NAMS), Harmony Biosciences (HRMY), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Mirum Pharmaceuticals Belite Bio Denali Therapeutics Recursion Pharmaceuticals Biohaven Bausch Health Companies Tarsus Pharmaceuticals NewAmsterdam Pharma Harmony Biosciences Ascentage Pharma Group International Mirum Pharmaceuticals (NASDAQ:MIRM) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Which has more risk & volatility, MIRM or KROS? Mirum Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Keros Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Does the media favor MIRM or KROS? In the previous week, Keros Therapeutics had 5 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 11 mentions for Keros Therapeutics and 6 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.18 beat Keros Therapeutics' score of 0.58 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer MIRM or KROS? Mirum Pharmaceuticals received 67 more outperform votes than Keros Therapeutics when rated by MarketBeat users. Likewise, 75.86% of users gave Mirum Pharmaceuticals an outperform vote while only 69.89% of users gave Keros Therapeutics an outperform vote. CompanyUnderperformOutperformMirum PharmaceuticalsOutperform Votes13275.86% Underperform Votes4224.14% Keros TherapeuticsOutperform Votes6569.89% Underperform Votes2830.11% Do analysts recommend MIRM or KROS? Mirum Pharmaceuticals presently has a consensus target price of $58.20, indicating a potential upside of 48.85%. Keros Therapeutics has a consensus target price of $40.33, indicating a potential upside of 186.66%. Given Keros Therapeutics' higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Keros Therapeutics 0 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has better earnings and valuation, MIRM or KROS? Keros Therapeutics has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$336.89M5.69-$163.41M-$1.85-21.14Keros Therapeutics$3.55M160.76-$152.99M-$5.01-2.81 Is MIRM or KROS more profitable? Mirum Pharmaceuticals has a net margin of -31.69% compared to Keros Therapeutics' net margin of -27,890.94%. Mirum Pharmaceuticals' return on equity of -41.22% beat Keros Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-31.69% -41.22% -14.81% Keros Therapeutics -27,890.94%-41.74%-38.42% Do institutionals & insiders have more ownership in MIRM or KROS? 71.6% of Keros Therapeutics shares are owned by institutional investors. 22.9% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 22.9% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryMirum Pharmaceuticals beats Keros Therapeutics on 11 of the 19 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$570.71M$6.44B$5.29B$7.35BDividend YieldN/A3.25%5.12%4.31%P/E Ratio-2.706.8821.7117.77Price / Sales160.76231.36379.3997.68Price / CashN/A65.6738.2234.64Price / Book1.275.916.443.98Net Income-$152.99M$142.72M$3.21B$247.44M7 Day Performance14.95%7.98%5.24%4.44%1 Month Performance21.08%-13.91%-9.49%-7.73%1 Year Performance-76.26%-9.98%11.01%1.28% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics3.4729 of 5 stars$14.07+4.0%$40.33+186.7%-76.3%$570.71M$3.55M-2.70100MIRMMirum Pharmaceuticals3.9657 of 5 stars$39.57-4.6%$58.20+47.1%+63.9%$1.94B$336.89M-19.59140Positive NewsBLTEBelite Bio2.6261 of 5 stars$58.01+5.3%$96.67+66.6%+74.5%$1.85BN/A-52.2610Short Interest ↓Analyst RevisionDNLIDenali Therapeutics4.1025 of 5 stars$12.33-4.1%$37.57+204.7%-24.3%$1.79B$330.53M-4.47430RXRXRecursion Pharmaceuticals2.1814 of 5 stars$4.32-7.1%$8.25+91.0%-26.4%$1.74B$58.49M-2.82400BHVNBiohaven3.6463 of 5 stars$16.75-10.3%$62.77+274.7%-53.8%$1.71BN/A-1.79239Analyst RevisionBHCBausch Health Companies4.0918 of 5 stars$4.63-7.8%$7.17+54.8%-40.8%$1.70B$9.63B-38.5819,900Short Interest ↑TARSTarsus Pharmaceuticals2.8573 of 5 stars$43.21-5.8%$63.67+47.3%+43.1%$1.66B$182.95M-11.3450Positive NewsNAMSNewAmsterdam Pharma2.6262 of 5 stars$14.94-5.8%$43.33+190.0%-18.5%$1.64B$45.56M-5.754Short Interest ↑HRMYHarmony Biosciences4.5507 of 5 stars$28.20-3.0%$53.33+89.1%-2.5%$1.62B$714.73M13.36200Short Interest ↓Positive NewsAAPGAscentage Pharma Group InternationalN/A$18.50-2.6%N/AN/A$1.61B$980.65M0.00600Positive News Related Companies and Tools Related Companies Mirum Pharmaceuticals Alternatives Belite Bio Alternatives Denali Therapeutics Alternatives Recursion Pharmaceuticals Alternatives Biohaven Alternatives Bausch Health Companies Alternatives Tarsus Pharmaceuticals Alternatives NewAmsterdam Pharma Alternatives Harmony Biosciences Alternatives Ascentage Pharma Group International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KROS Stock Free KROS Stock Alerts